NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell (MSC) therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications. …
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 Australian Biotech
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News